Vascular Targeting for Radioimmunotherapy with 213Bi

Stephen Kennel, Saed Mirzadeh

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Effective targeting of short-lived α-emitters such as 213Bi can be accomplished only with agents that localize rapidly. One such approach uses MAbs that bind to the luminal side of tumor vasculature. MAbs 34A and 201B bind to in urine thrombomodulin which is found in lung endothelium. These MAbs were derivatized with CHXb-DTPA and bound 213Bi. The labeled MAbs were shown to deliver over 50% of the injected dose to mouse lungs. The 213Bi remained in the lungs with a t1/2 > 4 h, and there was only slight deposition of isotope at other sites (kidney, liver, spleen). 213Bi coupled to MAb was shown to kill tumor cells in tissue culture efficiently. Injection of large doses (600 μCi) of 213Bi MAb 201 into mice that had previously been injected with EMT-6 tumor cells to form lung colonies resulted in hemorrhage in tumor and normal lung tissue at 4 days post injection. Lower doses (<300 μCi/animal) were better tolerated in normal tissue. Successful targeting of 213Bi to tumor vasculature has been accomplished in this model system and has significant promise for therapy in humans when appropriate targeting reagents are identified.

Original languageEnglish (US)
Pages (from-to)87-91
Number of pages5
JournalRadiochimica Acta
Volume79
Issue number2
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

lungs
Tumors
tumors
dosage
mice
Cells
Tissue
injection
endothelium
hemorrhages
Thrombomodulin
Tissue culture
Pentetic Acid
spleen
urine
kidneys
liver
Isotopes
Liver
reagents

All Science Journal Classification (ASJC) codes

  • Physical and Theoretical Chemistry

Cite this

Vascular Targeting for Radioimmunotherapy with 213Bi. / Kennel, Stephen; Mirzadeh, Saed.

In: Radiochimica Acta, Vol. 79, No. 2, 01.01.1997, p. 87-91.

Research output: Contribution to journalArticle

Kennel, Stephen ; Mirzadeh, Saed. / Vascular Targeting for Radioimmunotherapy with 213Bi. In: Radiochimica Acta. 1997 ; Vol. 79, No. 2. pp. 87-91.
@article{1206d303a3fc4222a04fcb56778152f5,
title = "Vascular Targeting for Radioimmunotherapy with 213Bi",
abstract = "Effective targeting of short-lived α-emitters such as 213Bi can be accomplished only with agents that localize rapidly. One such approach uses MAbs that bind to the luminal side of tumor vasculature. MAbs 34A and 201B bind to in urine thrombomodulin which is found in lung endothelium. These MAbs were derivatized with CHXb-DTPA and bound 213Bi. The labeled MAbs were shown to deliver over 50{\%} of the injected dose to mouse lungs. The 213Bi remained in the lungs with a t1/2 > 4 h, and there was only slight deposition of isotope at other sites (kidney, liver, spleen). 213Bi coupled to MAb was shown to kill tumor cells in tissue culture efficiently. Injection of large doses (600 μCi) of 213Bi MAb 201 into mice that had previously been injected with EMT-6 tumor cells to form lung colonies resulted in hemorrhage in tumor and normal lung tissue at 4 days post injection. Lower doses (<300 μCi/animal) were better tolerated in normal tissue. Successful targeting of 213Bi to tumor vasculature has been accomplished in this model system and has significant promise for therapy in humans when appropriate targeting reagents are identified.",
author = "Stephen Kennel and Saed Mirzadeh",
year = "1997",
month = "1",
day = "1",
doi = "10.1524/ract.1997.79.2.87",
language = "English (US)",
volume = "79",
pages = "87--91",
journal = "Radiochimica Acta",
issn = "0033-8230",
publisher = "R. Oldenbourg",
number = "2",

}

TY - JOUR

T1 - Vascular Targeting for Radioimmunotherapy with 213Bi

AU - Kennel, Stephen

AU - Mirzadeh, Saed

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Effective targeting of short-lived α-emitters such as 213Bi can be accomplished only with agents that localize rapidly. One such approach uses MAbs that bind to the luminal side of tumor vasculature. MAbs 34A and 201B bind to in urine thrombomodulin which is found in lung endothelium. These MAbs were derivatized with CHXb-DTPA and bound 213Bi. The labeled MAbs were shown to deliver over 50% of the injected dose to mouse lungs. The 213Bi remained in the lungs with a t1/2 > 4 h, and there was only slight deposition of isotope at other sites (kidney, liver, spleen). 213Bi coupled to MAb was shown to kill tumor cells in tissue culture efficiently. Injection of large doses (600 μCi) of 213Bi MAb 201 into mice that had previously been injected with EMT-6 tumor cells to form lung colonies resulted in hemorrhage in tumor and normal lung tissue at 4 days post injection. Lower doses (<300 μCi/animal) were better tolerated in normal tissue. Successful targeting of 213Bi to tumor vasculature has been accomplished in this model system and has significant promise for therapy in humans when appropriate targeting reagents are identified.

AB - Effective targeting of short-lived α-emitters such as 213Bi can be accomplished only with agents that localize rapidly. One such approach uses MAbs that bind to the luminal side of tumor vasculature. MAbs 34A and 201B bind to in urine thrombomodulin which is found in lung endothelium. These MAbs were derivatized with CHXb-DTPA and bound 213Bi. The labeled MAbs were shown to deliver over 50% of the injected dose to mouse lungs. The 213Bi remained in the lungs with a t1/2 > 4 h, and there was only slight deposition of isotope at other sites (kidney, liver, spleen). 213Bi coupled to MAb was shown to kill tumor cells in tissue culture efficiently. Injection of large doses (600 μCi) of 213Bi MAb 201 into mice that had previously been injected with EMT-6 tumor cells to form lung colonies resulted in hemorrhage in tumor and normal lung tissue at 4 days post injection. Lower doses (<300 μCi/animal) were better tolerated in normal tissue. Successful targeting of 213Bi to tumor vasculature has been accomplished in this model system and has significant promise for therapy in humans when appropriate targeting reagents are identified.

UR - http://www.scopus.com/inward/record.url?scp=0002433917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0002433917&partnerID=8YFLogxK

U2 - 10.1524/ract.1997.79.2.87

DO - 10.1524/ract.1997.79.2.87

M3 - Article

VL - 79

SP - 87

EP - 91

JO - Radiochimica Acta

JF - Radiochimica Acta

SN - 0033-8230

IS - 2

ER -